Rosuvastatin Calcium Patent Expiration
Rosuvastatin Calcium was first introduced by Astrazeneca Uk Ltd
Rosuvastatin Calcium Patents
Given below is the list of patents protecting Rosuvastatin Calcium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ezallor Sprinkle | US10413543 | Stable multiparticulate pharmaceutical composition of rosuvastatin | Feb 12, 2036 | Sun Pharm |
| Crestor |
US6858618 (Pediatric) | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Jun 17, 2022
(Expired) | Astrazeneca |
| Crestor | US6858618 | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Dec 17, 2021
(Expired) | Astrazeneca |
| Crestor |
US6316460 (Pediatric) | Pharmaceutical compositions |
Feb 04, 2021
(Expired) | Astrazeneca |
| Crestor | US6316460 | Pharmaceutical compositions |
Aug 04, 2020
(Expired) | Astrazeneca |
| Crestor |
US7030152 (Pediatric) | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct 02, 2018
(Expired) | Astrazeneca |
| Crestor |
US7964614 (Pediatric) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct 02, 2018
(Expired) | Astrazeneca |
| Crestor | US7030152 | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr 02, 2018
(Expired) | Astrazeneca |
| Crestor | US7964614 | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr 02, 2018
(Expired) | Astrazeneca |
| Crestor |
USRE37314 (Pediatric) | Pyrimidine derivatives |
Jul 08, 2016
(Expired) | Astrazeneca |
| Crestor | USRE37314 | Pyrimidine derivatives |
Jan 08, 2016
(Expired) | Astrazeneca |
Rosuvastatin Calcium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rosuvastatin Calcium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis | Beijing Inno Medicine Co., Ltd. | NA |
COMPLETED
(Sep 1, 2026)
| PHASE1, PHASE2 |
| Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects | Beijing Inno Medicine Co., Ltd. | NA |
COMPLETED
(Sep 1, 2026)
| PHASE1 |
| Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants | Neurodawn Pharmaceutical Co., Ltd. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |